Observational Cohort Study of Immune Checkpoint Inhibitor Therapy for Anaplastic and Poorly Differentiated Thyroid Carcinoma

被引：0
|
作者：
Elghawy, O. [1 ]
Sun, L. [2 ]
机构：
[1] Univ Penn, Dept Hematol & Oncol, Philadelphia, PA 19104 USA
[2] Univ Penn, Philadelphia, PA 19104 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 118卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
240
引用
收藏
页码：E78 / E79
页数：2
相关论文
共 50 条
  • [41] Final Data from the ATLEP Phase II Study: Lenvatinib and Pembrolizumab in anaplastic and poorly differentiated Thyroid Carcinoma
    Dierks, C.
    Ruf, J.
    Klein, C.
    Seufert, J.
    Kroiss, M.
    La Rosee, P.
    Spitzweg, C.
    Kreissl, M.
    Binder, M.
    Von Bubnoff, N.
    Miething, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 154 - 154
  • [42] An Evanishing Thyroid During Immune Checkpoint Inhibitor Therapy
    Cuzzocrea, Marco
    Paone, Gaetano
    Ceriani, Luca
    Giovanella, Luca
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (03) : 253 - 254
  • [43] Thyroid disorders during immune checkpoint inhibitor therapy
    Theiler-Schwetz, Verena
    Trummer, Christian
    Richtig, Erika
    Richtig, Georg
    Pilz, Stefan
    AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, 2020, 13 (03): : 115 - 118
  • [44] Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers
    Lancia, Inigo
    Ibrahimpasic, Tihana
    Boucai, Laura
    Sinha, Rileen
    Knauf, Jeffrey A.
    Shah, Ronak H.
    Dogan, Snjezana
    Ricarte-Filho, Julio C.
    Krishnamoorthy, Gnana P.
    Xu, Bin
    Schultz, Nikolaus
    Berger, Michael F.
    Sander, Chris
    Taylor, Barry S.
    Ghossein, Ronald
    Ganly, Ian
    Fagin, James A.
    JOURNAL OF CLINICAL INVESTIGATION, 2016, 126 (03): : 1052 - 1066
  • [45] Anaplastic and Poorly Differentiated Thyroid Carcinoma: Therapeutic Strategies and Treatment Outcome of 52 Consecutive Patients
    Siironen, P.
    Hagstrom, J.
    Maenpaa, H. O.
    Louhimo, J.
    Heikkila, A.
    Heiskanen, I.
    Arola, J.
    Haglund, C.
    ONCOLOGY, 2010, 79 (5-6) : 400 - 408
  • [46] Real word outcomes of cabozantinib therapy in poorly differentiated thyroid carcinoma
    Elghawy, Omar
    Barsouk, Adam
    Xu, Jessica
    Chen, Simon
    Cohen, Roger B.
    Sun, Lova
    EUROPEAN THYROID JOURNAL, 2024, 13 (06)
  • [47] ULTRASTRUCTURAL-STUDY OF POORLY DIFFERENTIATED MEDULLARY CARCINOMA OF THE THYROID
    KAKUDO, K
    MIYAUCHI, A
    KATAYAMA, S
    WATANABE, K
    VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1987, 410 (05) : 455 - 460
  • [48] Immune checkpoint inhibitor rechallenge in advanced hepatocellular carcinoma: A retrospective cohort study
    Chen, J-K.
    Su, J-Y.
    Peng, N-F.
    Ma, L.
    Zhong, J-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1490 - S1490
  • [49] An Evaluation of Clinical Efficacy of Immune Checkpoint Inhibitors for Patients with Anaplastic Thyroid Carcinoma
    Hatashima, Alycia
    Archambeau, Brianna
    Armbruster, Heather
    Xu, Menglin
    Shah, Manisha
    Konda, Bhavana
    Lott Limbach, Abberly
    Sukrithan, Vineeth
    THYROID, 2022, 32 (08) : 926 - 936
  • [50] Poorly differentiated thyroid carcinoma An underdiagnosed entity
    Dettmer, M. S.
    Schmitt, A.
    Komminoth, P.
    Perren, A.
    PATHOLOGE, 2020, 41 (SUPPL 1): : 1 - 8
12345